$2.07 Earnings Per Share Expected for Pfizer Inc. (NYSE:PFE) This Quarter

Wall Street analysts expect that Pfizer Inc. (NYSE:PFEGet Rating) will post $2.07 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Pfizer’s earnings, with the lowest EPS estimate coming in at $1.54 and the highest estimate coming in at $2.59. Pfizer posted earnings of $1.07 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 93.5%. The firm is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Pfizer will report full-year earnings of $6.61 per share for the current financial year, with EPS estimates ranging from $6.37 to $7.31. For the next fiscal year, analysts forecast that the business will report earnings of $5.14 per share, with EPS estimates ranging from $4.20 to $5.63. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Pfizer.

Pfizer (NYSE:PFEGet Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing the consensus estimate of $1.66 by ($0.04). The company had revenue of $25.66 billion during the quarter, compared to analysts’ expectations of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm’s revenue for the quarter was up 76.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.93 EPS.

Several analysts have recently issued reports on PFE shares. Barclays set a $52.00 target price on shares of Pfizer in a research report on Wednesday, May 4th. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research report on Tuesday, May 3rd. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $52.00 target price on the stock. in a research report on Tuesday, February 15th. StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 19th. Finally, Wells Fargo & Company reduced their price objective on shares of Pfizer from $60.00 to $55.00 in a research report on Wednesday, May 4th. Eleven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Buy” and an average price target of $57.05.

Shares of PFE stock opened at $50.67 on Friday. The stock has a market cap of $284.30 billion, a P/E ratio of 11.62, a PEG ratio of 0.60 and a beta of 0.76. Pfizer has a 52 week low of $38.47 and a 52 week high of $61.71. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43. The company’s fifty day simple moving average is $51.34 and its two-hundred day simple moving average is $52.02.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 10th. Investors of record on Friday, May 13th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, May 12th. This represents a $1.60 annualized dividend and a dividend yield of 3.16%. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.

In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the transaction, the executive vice president now owns 38,146 shares of the company’s stock, valued at $1,907,300. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.05% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in PFE. Norges Bank acquired a new stake in shares of Pfizer in the fourth quarter valued at about $3,351,891,000. Vanguard Group Inc. boosted its position in Pfizer by 3.0% during the first quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock worth $24,801,210,000 after acquiring an additional 13,790,348 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in Pfizer by 577.8% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock worth $715,270,000 after acquiring an additional 10,440,786 shares during the last quarter. Coatue Management LLC acquired a new position in Pfizer during the fourth quarter worth about $608,919,000. Finally, Franklin Resources Inc. boosted its position in Pfizer by 28.8% during the third quarter. Franklin Resources Inc. now owns 45,980,291 shares of the biopharmaceutical company’s stock worth $1,977,614,000 after acquiring an additional 10,270,562 shares during the last quarter. Institutional investors and hedge funds own 66.50% of the company’s stock.

About Pfizer (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More

Get a free copy of the Zacks research report on Pfizer (PFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.